X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs PFIZER - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD PFIZER BIOCON LTD/
PFIZER
 
P/E (TTM) x 51.4 34.3 149.8% View Chart
P/BV x 7.5 4.8 154.4% View Chart
Dividend Yield % 0.2 0.7 22.0%  

Financials

 BIOCON LTD   PFIZER
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
PFIZER
Mar-18
BIOCON LTD/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,1882,365 50.2%   
Low Rs3051,625 18.8%   
Sales per share (Unadj.) Rs68.7430.3 16.0%  
Earnings per share (Unadj.) Rs7.678.7 9.6%  
Cash flow per share (Unadj.) Rs14.093.2 15.0%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.11.0 13.4%  
Book value per share (Unadj.) Rs86.3586.5 14.7%  
Shares outstanding (eoy) m600.0045.75 1,311.5%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.94.6 234.3%   
Avg P/E ratio x98.925.3 390.0%  
P/CF ratio (eoy) x53.421.4 249.6%  
Price / Book Value ratio x8.63.4 254.2%  
Dividend payout %13.225.4 52.1%   
Avg Mkt Cap Rs m447,90091,271 490.7%   
No. of employees `0006.12.6 233.8%   
Total wages/salary Rs m9,3113,143 296.3%   
Avg. sales/employee Rs Th6,705.87,484.8 89.6%   
Avg. wages/employee Rs Th1,514.21,195.0 126.7%   
Avg. net profit/employee Rs Th736.91,369.1 53.8%   
INCOME DATA
Net Sales Rs m41,23419,685 209.5%  
Other income Rs m2,0621,143 180.4%   
Total revenues Rs m43,29620,828 207.9%   
Gross profit Rs m8,2915,003 165.7%  
Depreciation Rs m3,851663 581.3%   
Interest Rs m6154 14,642.9%   
Profit before tax Rs m5,8875,479 107.4%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5691,878 83.5%   
Profit after tax Rs m4,5313,601 125.8%  
Gross profit margin %20.125.4 79.1%  
Effective tax rate %26.734.3 77.7%   
Net profit margin %11.018.3 60.1%  
BALANCE SHEET DATA
Current assets Rs m41,48624,167 171.7%   
Current liabilities Rs m21,4139,544 224.4%   
Net working cap to sales %48.774.3 65.5%  
Current ratio x1.92.5 76.5%  
Inventory Days Days6455 116.1%  
Debtors Days Days9429 328.1%  
Net fixed assets Rs m50,6619,514 532.5%   
Share capital Rs m3,000458 655.7%   
"Free" reserves Rs m48,80826,375 185.1%   
Net worth Rs m51,80826,832 193.1%   
Long term debt Rs m17,89825 71,592.0%   
Total assets Rs m99,89736,900 270.7%  
Interest coverage x10.61,305.5 0.8%   
Debt to equity ratio x0.30 37,078.4%  
Sales to assets ratio x0.40.5 77.4%   
Return on assets %5.29.8 52.7%  
Return on equity %8.713.4 65.2%  
Return on capital %9.620.4 47.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05822 53,830.4%   
Fx outflow Rs m7,3481,489 493.6%   
Net fx Rs m4,710-1,466 -321.2%   
CASH FLOW
From Operations Rs m6,6213,318 199.5%  
From Investments Rs m-6,840-2,383 287.0%  
From Financial Activity Rs m-2,397-1,104 217.2%  
Net Cashflow Rs m-2,612-169 1,550.1%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 63.9 32.2%  
Indian inst/Mut Fund % 8.4 7.5 112.0%  
FIIs % 10.7 4.9 218.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 23.7 84.0%  
Shareholders   109,995 85,207 129.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   CIPLA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Capital Infusion in PSBs, November WPI Inflation, and Top Cues in Focus Today(Pre-Open)

Indian share markets closed marginally higher on Friday. Gains were largely seen in the telecom sector and oil & gas sector, while healthcare stocks witnessed selling pressure.

Related Views on News

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Dec 14, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS